Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
Revelation Biosciences (NASDAQ:REVB) reported financial results for the three and six months ended June 30, 2026. Cash and cash equivalents rose to $11.5M from $10.7M at Dec. 31, 2025, and it expects funding through Q1 2027. Net loss was $3.3M ($0.87/share) for Q2 and $6.3M ($3.41/share) for six months. The company also advanced Gemini AKI Phase 2/3 start-up and formed an AKI advisory board.
How this was made
The 30-second read
Why it matters
The key tradable elements are updated financials (cash, burn, net loss) and management’s runway statement, plus continued Phase 2/3 start-up progress for GEM-AKI.
Market read
This is a company-specific financial update with a stated cash runway through Q1 2027 and ongoing clinical start-up activity, but no new clinical outcome or regulatory decision.
What to watch
The article highlights AKI advisory board formation and Gemini market assessment TAM, but does not provide enrollment timing confirmation or any new Phase 2/3 efficacy data, which may be what the market ultimately prices.
Background
Revelation Biosciences is a clinical-stage company developing Gemini, a TLR4 agonist formulation, across acute kidney injury and other inflammatory indications.
Ticker impact
Revelation reported cash of $11.5M at June 30, 2026 and said it funds operations through Q1 2027, alongside higher net losses.
Likely modest, sentiment-driven reaction unless investors view the cash runway and burn as improving versus expectations.
The release provides balance-sheet runway guidance (through Q1 2027) and updated operating/burn figures, but no new clinical efficacy or regulatory milestone.
Market effects
Adds another data point on funding runway and burn dynamics for clinical-stage biotech, which can influence risk appetite for similar small-cap names.
Limited, primarily impacts US small-cap biotech sentiment.
Low, as the disclosure is company-specific and not tied to a global macro or regulatory event.
Counterpoint
Investors may treat the higher cash balance and stated funding runway through Q1 2027 as reducing immediate dilution risk, offsetting the larger net loss.
Key entities
- companyRevelation Biosciences, Inc.
Clinical-stage life sciences company developing Gemini for inflammatory diseases, including acute kidney injury.
- product_candidateGemini (PHAD, TLR4 agonist)
Proprietary formulation being evaluated in GEM-AKI and other indications.
- program_updateAcute Kidney Injury Advisory Board
Advisory board formation and expansion tied to the upcoming Phase 2/3 AKI trial.
